Kyverna Reports Positive Miv-cel Trial Results in Stiff Person Syndrome

Kyverna Therapeutics, Inc. announced positive primary analysis results from its registrational trial, KYSA-8, for miv-cel (KYV-101) in stiff person syndrome (SPS). The trial demonstrated statistically significant and durable clinical benefit across all endpoints, with a single dose achieving robust and durable improvements in mobility. This positive outcome could significantly advance the development of miv-cel as a treatment for SPS.